Bavarian Nordic A/S $ 11.90 0.55 (4.85%)
Warning! GuruFocus has detected 3 Severe warning signs with BVNRY. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for Bavarian Nordic A/S () from 2013 to Mar 06 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Bavarian Nordic A/S stock (BVNRY) PE ratio as of Mar 06 2021 is 14.42. More Details
Bavarian Nordic A/S PE Ratio (TTM) Historical Data
View and export this data going back to 2013. Start your Free Trial
Bavarian Nordic A/S PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare OCSE:ZEAL OCSE:ALK B OCSE:ORPHA OCSE:NOVO B ASX:CSL NAS:VRTX NAS:REGN XKRX:207940 NAS:SGEN NAS:MRNA NAS:ALXN XKRX:068270 NAS:INCY HKSE:02269 OCSE:GMAB HKSE:01177 SZSE:300122 NAS:BMRN XBRU:UCB NAS:ALNY
Address Hejreskovvej 10A, Kvistgaard, DNK, 3490
Bavarian Nordic is a biotechnology company focused on the development, manufacturing, and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company has a specific focus on diseases for which the unmet medical need is high. Bavarian generates revenue through government research and development and supply contracts, and from its commercial partnerships. The vast majority of the company's revenue is generated in the Netherlands, followed by the United States, Canada, and other geographic markets.